A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerance, Dose-Limiting Toxicity (DLT),
Maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 (OX40 Agonist)
administered as a single agent in patients with advanced solid tumors.